Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Dengue Vaccine Market Value Growth And Long-Term Outlook
The dengue vaccine market has experienced rapid expansion in recent times. Projections indicate it will expand from $0.51 billion in 2025 to reach $0.61 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 20.2%. Historically, this growth is a result of several factors including an increase in dengue infection rates, the scarcity of initial vaccines, a heightened public health burden, increasing recognition of mosquito-borne illnesses, and the implementation of early government intervention strategies.
The dengue vaccine market size is anticipated to experience substantial growth over the next few years. It is projected to reach $1.16 billion by 2030, expanding at a compound annual growth rate (CAGR) of 17.3%. This expansion in the forecast period can be attributed to factors such as the broadening of immunization programs, increasing investment in vaccine research, elevated healthcare spending in endemic countries, a heightened focus on multi-strain vaccine efficacy, and swifter regulatory approvals. Significant trends anticipated during this period include a rising global emphasis on dengue prevention, the proliferation of government-led vaccination initiatives, increasing adoption of tetravalent dengue vaccines, an expansion of public health funding in endemic regions, and a growing demand for pediatric immunization solutions.
Get A Free Sample Report With In-Depth Market Insights:
Dengue Vaccine Market Growth Factors Behind Sustained Expansion
The increasing prevalence of dengue fever cases is projected to fuel the expansion of the dengue vaccine markets in the future. This viral illness, transmitted by Aedes aegypti mosquitoes, manifests with symptoms such as elevated temperature, headaches, aching joints, and skin eruptions. Factors contributing to the surge in dengue fever incidents include shifting climate patterns, increasing urbanization, insufficient mosquito management, and the ongoing evolution of the virus. The dengue vaccine operates by stimulating the immune system to recognize and fight against the dengue virus. It mitigates the severity of the infection and lowers the likelihood of serious complications, thereby contributing to a reduction in both cases and hospital admissions. As an illustration, the World Health Organization, a Switzerland-based intergovernmental organization, reported in May 2024 that in the American region, dengue occurrences exceeded 7 million by April 2024, an increase from the 4.6 million cases recorded in 2023. Consequently, the escalating incidence of dengue fever is propelling the expansion of the dengue vaccine market.
Dengue Vaccine Market Breakdown By Product Type And Application
The dengue vaccine market covered in this report is segmented –
1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users
Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine
Dengue Vaccine Market Industry Trends Fueling Future Revenue Growth
Leading firms within the dengue vaccine market are prioritizing clinical investigations to create advanced formulations, specifically live attenuated vaccines, intended to offer comprehensive, durable defense against all four dengue virus serotypes. These live attenuated vaccines utilize an attenuated viral form, incapable of causing illness in healthy people, yet they prompt the immune system to build robust, enduring, and extensive immunity, preparing the body to effectively identify and combat the actual virus upon subsequent exposure. As an illustration, in June 2025, the US pharmaceutical firm Merck & Co. Inc. commenced the MOBILIZE-1 Phase 3 clinical trial for assessing V181, its experimental live attenuated quadrivalent dengue vaccine. This study intends to enlist around 12,000 healthy children and adolescents, ranging from 2 to 17 years old, within dengue-endemic nations across the Asia-Pacific region, such as Indonesia, Malaysia, Philippines, Singapore, Thailand, and Vietnam. The trial employs a randomized, double-blind, placebo-controlled design to ascertain the safety, immunogenicity, and effectiveness of a single V181 dose against all four dengue virus serotypes, irrespective of previous dengue exposure. The vaccine aims to address symptomatic dengue of any degree, including severe manifestations necessitating hospitalization, striving to deliver extensive, durable protection to mitigate the worldwide impact of this swiftly propagating mosquito-borne illness.
Dengue Vaccine Market Company Landscape And Competitive Strategy
Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.
View The Full Dengue Vaccine Market Report:
Dengue Vaccine Market Geographic Landscape: Which Region Dominates Industry Growth?
Asia-Pacific was the largest region in the dengue vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
